Advanced in Temporal Arteritis

Ygal Benhamou

CHU Marseille
Marseille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Temporal Arteritis
CHU Marseille
Marseille, FR 
OverviewLocationsClinical Research

Overview

Ygal Benhamou practices in Marseille, France. Benhamou is rated as an Advanced expert by MediFind in the treatment of Temporal Arteritis. Their top areas of expertise are Purpura, Thrombocytopenia, Blood Clots, Antiphospholipid Syndrome, and Thrombectomy.

Their clinical research consists of co-authoring 167 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Temporal Arteritis.

Locations

CHU Marseille
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Enrollment Status: Recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Study in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) to Evaluate the Pharmacokinetics, Safety and Efficacy of rADAMTS-13 (SHP655) Administered in Addition to Standard Of Care (SoC) Treatment
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Study in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) to Evaluate the Pharmacokinetics, Safety and Efficacy of rADAMTS-13 (SHP655) Administered in Addition to Standard Of Care (SoC) Treatment
Enrollment Status: Completed
Publish Date: December 01, 2022
Intervention Type: Other, Drug
Study Drug: SHP655
Study Phase: Phase 2
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban, Heparin, VKA
Study Phase: Phase 3
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Enrollment Status: Completed
Publish Date: August 25, 2022
Intervention Type: Other
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
View 5 Less Clinical Trials

167 Total Publications

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Benhamou's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 49 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile